The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Oral clodronate in breast cancer patients with bone metastases: a randomized study
Open accessAbstract
Objectives. To investigate the effect of the bisphosphonate clodronate on the occurrence of skeletal events (hypercalcaemia, fractures and radiotherapy) in breast cancer patients with bone metastases. Design. Prospective, randomized, controlled, clinical trial. Setting. A department of oncology in a university hospital. Subjects. One hundred patients who received first‐line systemic antineoplastic treatment for metastatic breast cancer with bone involvement were randomized to receive clodronate as two 400 mg capsules twice a day for 2 years or no additional therapy. Results. In the clodronate group the number of skeletal events was reduced to 14 events in 48 evaluable patients as compared with 21 events in 51 evaluable control patients. The time to the first skeletal event was significantly longer in the clodronate group than in the control group (P = 0.015) and the most distinct difference was a lower occurrence of fractures in the clodronate group (P = 0.023). After 15 months the effect of clodronate tended to decline as the need for radiotherapy increased in the clodronate group compared with the control group (P = 0.069). Significant improvements in several quality‐of‐life aspects were seen in both groups during the first 6 months, but there was no significant difference between the groups. No effect was observed on time to radiologically evaluated disease progression in bone or on survival. The most frequent side‐effects resulting in discontinuation of clodronate were nausea and diarrhoea. Conclusion. Oral clodronate is associated with a temporary reduction of morbidity related to bone metastases in breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Cited by
A systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Bisphosphonates: Clinical Experience
Coleman, R. E. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-14 · Cited by 384
The Cancer Patient and Quality of Life
Bottomley, A. (2002) · The Oncologist · doi:10.1634/theoncologist.7-2-120 · Cited by 378
Bisphosphonates for breast cancer
Pavlakis, N., & Stockler, M. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474 · Cited by 360
Metadata
- Authors
- Kristensen, B., Ejlertsen, B., Groenvold, M., Hein, S., Loft, H., & Mouridsen, H. T.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 1999-07
- Volume
- 246
- Issue
- 1
- Pages
- 67-74
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2037542472
- Cited by
- 176
- References
- 1
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral clodronate in breast cancer patients with bone metastases: a randomized study. https://app.cochat.ai/papers/10.1046/j.1365-2796.1999.00507.x
- The paper
- Kristensen, B., Ejlertsen, B., Groenvold, M., Hein, S., Loft, H., & Mouridsen, H. T. (1999). Oral clodronate in breast cancer patients with bone metastases: a randomized study. Journal of Internal Medicine. https://doi.org/10.1046/j.1365-2796.1999.00507.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.